Using an analytical approach similar to that described above for the MCA mouse models to predict neoantigens, we combined exome sequencing with algorithmic prediction of MHC binding to compare tumor-unique peptides with their wild-type counterparts in a small clinical trial of patients with melanoma. Here, HLA-C is linked to neoplasm.